Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

The Feasibility Of High-dose Chemotherapy In Breast Cancer Patients With Impaired Left Ventricular Function

M. Rose, F. Lee, A. Gollerkeri, E. D'Ándrea, A. Psyrri, T. Bdolah-Abram, B. Burtness
Published 2000 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Breast cancer patients with cardiac disease are usually excluded from clinical trials of high-dose chemotherapy. We treated 52 patients with inflammatory and/or metastatic disease with sequential high-dose melphalan and stem cell rescue followed by high-dose thiotepa and stem cell rescue. Stem cells were mobilized with cyclophosphamide and/or paclitaxel and filgrastim. Left ventricular ejection fraction (LVEF) was measured by equilibrium radionuclide angiocardiography (ERNA) at baseline, after each course of chemotherapy and 4 weeks after completing both transplants. The mean absolute decrease in LVEF after the two transplants was 3.6% (P = 0.008 for the comparison with baseline LVEF), and most of this drop (−2.5%, P = 0.007) occurred after mobilization. Unexpectedly, paclitaxel was associated with a mean absolute decrease in LVEF of 3.4% (P = 0.032, n = 19), cyclophosphamide alone was not associated with a significant change in LVEF (−1.3%, P = 0.23), but mobilization with sequential paclitaxel and cyclophosphamide resulted in a mean absolute drop of 4.9% in LVEF (P = 0.009). Twelve patients were found to have a reduced LVEF (<50%) at least once during treatment and had a mean absolute decrease in lvef of 10% (P = 0.008) from baseline, compared with a drop of only 1.8% (P = 0.176) in the patients without impaired LV function. Although two of these 12 patients developed symptomatic heart failure, their cardiac symptoms were easily treated and there were no cardiac deaths. We conclude that our protocol has acceptable cardiac toxicity and breast cancer patients with impaired LV function should not be denied high-dose chemotherapy if otherwise indicated. Bone Marrow Transplantation (2000) 26, 133–139.
This paper references
[Phase I study].
T. Taguchi (1995)
Paclitaxel-induced cardiotoxicity. An ultrastructural study.
T. Shek (1996)
Cardiac disturbances during the administration of taxol.
E. Rowinsky (1991)
Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens.
A. Braverman (1991)
Doxorubicin-induced cardiomyopathy.
P. Singal (1998)
The biology and clinical uses of blood stem cells.
L. To (1997)
Anthracycline-induced cardiotoxicity.
K. Shan (1996)
Risk factors for doxorubicin-induced congestive heart failure.
D. V. Von Hoff (1979)
A phase I study of paclitaxel for mobilization of stem cells
BA Burtness (1999)
Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor.
M. Goldberg (1986)
Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography.
R. G. Schwartz (1987)
Use of dexrazoxane and other strategies to prevent cardiomyopathy associated with doxorubicin-taxane combinations.
J. Sparano (1998)
Subclin - ical disturbances in cardiac function at rest and in gas exchange during exercise are common findings after autologous bone marrow transplant
K Carlson (1994)
Patient selection in high-dose chemotherapy trials: relevance in high-risk breast cancer.
R. Garcia-Carbonero (1997)
Angiotensin converting enzyme inhibitors in bone marrow transplant recipients with depressed left ventricular function.
P. W. Kakavas (1995)
Rapid radionuclide-derived systolic and diastolic cardiac function using cycle-dependent background correction and Fourier analysis
FA Lee (1986)
The high-dose sequential (Milan) chemotherapy/PBSC transplantation regimen for patients with lymphoma is not cardiotoxic.
M. Ghielmini (1999)
Risk factors for doxorubicininduced congestive heart failure
DD VonHoff (1979)
A phase I study of paclitaxel for mobilization of peripheral blood progenitor cells
B. Burtness (1999)
Review of tests for monitoring doxorubicin-induced cardiomyopathy.
W. Ganz (1996)
Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood.
S. Lipshultz (1991)
Cardiotoxicity associated with high-dose cyclophosphamide therapy.
J. Gottdiener (1981)
Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography.
J. Alexander (1979)
Bone marrow transplant.
L. Davies (1985)
Fatal cyclophosphamide cardiomyopathy: its clinical course and treatment.
C. Lee (1996)
Cardiac effects of high-dose epirubicin and cyclophosphamide in women with poor prognosis breast cancer.
R. Basser (1999)
Comparison and reproducibility of visual echocardiographic and quantitative radionuclide left ventricular ejection fractions.
N. van Royen (1996)
Cardiac failure and dysrhythmias 6-19 years after anthracycline therapy: a series of 15 patients.
L. Steinherz (1995)
Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.
L. Gianni (1995)
Cardiotoxicity from intensive chemotherapy combined with radiotherapy in breast cancer.
H. de Graaf (1997)
Subclinical disturbances in cardiac function at rest and in gas exchange during exercise are common findings after autologous bone marrow transplantation.
K. Carlson (1994)
Cyclophosphamide toxicity. Characterising and avoiding the problem.
L. Fraiser (1991)

This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar